{"id":33257,"date":"2025-09-05T16:06:16","date_gmt":"2025-09-05T10:36:16","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=33257"},"modified":"2025-09-05T16:06:17","modified_gmt":"2025-09-05T10:36:17","slug":"cardiovascular-deals-2025","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/cardiovascular-deals-2025","title":{"rendered":"Key Cardiovascular Deals of 2025: Sealing the Heartbeat"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69ed0a7f819fe\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69ed0a7f819fe\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/cardiovascular-deals-2025\/#ProFound_Therapeutics_and_Novartis_Enter_Strategic_USD_750_million_Collaboration_to_Advance_Novel_Cardiovascular_Therapies_Using_Proteome-Based_Drug_Discovery\" >ProFound Therapeutics and Novartis Enter Strategic USD 750 million Collaboration to Advance Novel Cardiovascular Therapies Using Proteome-Based Drug Discovery&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/cardiovascular-deals-2025\/#Lilly_to_Acquire_Verve_Therapeutics_in_Deal_Worth_Up_to_USD_13_billion_to_Advance_One-Time_Gene_Editing_Therapies_Targeting_Cardiovascular_Disease\" >Lilly to Acquire Verve Therapeutics in Deal Worth Up to USD 1.3 billion to Advance One-Time Gene Editing Therapies Targeting Cardiovascular Disease<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/cardiovascular-deals-2025\/#Novartis_Completes_USD_31_billion_Acquisition_of_Anthos_Therapeutics_to_Advance_Abelacimab_a_Late-Stage_Factor_XI_Inhibitor_Targeting_Stroke_and_Cancer-Associated_Thrombosis\" >Novartis Completes USD 3.1 billion Acquisition of Anthos Therapeutics to Advance Abelacimab, a Late-Stage Factor XI Inhibitor Targeting Stroke and Cancer-Associated Thrombosis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/cardiovascular-deals-2025\/#Conclusion_Sealing_the_Next_Era_of_Cardiovascular_Innovation\" >Conclusion: Sealing the Next Era of Cardiovascular Innovation<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>The cardiovascular space has witnessed a surge in strategic collaborations and licensing deals as companies race to address the rising global burden of heart disease with next-generation therapies. Recent transactions reflect a sharpened focus on precision cardiology, novel protein targets, and <a href=\"https:\/\/www.delveinsight.com\/report-store\/rna-competitive-landscape\">RNA-based approaches<\/a>, underscoring the industry\u2019s shift toward innovation-driven growth. These alliances not only aim to bolster R&amp;D pipelines but also signal a broader trend of de-risking early assets through shared expertise and capital.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-profound-therapeutics-and-novartis-enter-strategic-usd-750-million-collaboration-to-advance-novel-cardiovascular-therapies-using-proteome-based-drug-discovery-nbsp\"><span class=\"ez-toc-section\" id=\"ProFound_Therapeutics_and_Novartis_Enter_Strategic_USD_750_million_Collaboration_to_Advance_Novel_Cardiovascular_Therapies_Using_Proteome-Based_Drug_Discovery\"><\/span><strong>ProFound Therapeutics and Novartis Enter Strategic USD 750 million Collaboration to Advance Novel Cardiovascular Therapies Using Proteome-Based Drug Discovery<\/strong>&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In <strong>June 2025<\/strong>, <strong>ProFound Therapeutics<\/strong> entered a <strong>4-year strategic collaboration<\/strong> with <strong>Novartis<\/strong> to advance novel cardiovascular therapies using its proprietary ProFoundry Platform. This partnership reflects a growing industry focus on mining the expanded proteome for previously unrecognized protein targets, with the potential to unlock first-in-class drug candidates.&nbsp;<\/p>\n\n\n\n<p>By combining ProFound\u2019s deep proteomic discovery capabilities with Novartis\u2019s established strength in cardiovascular research and development, the deal positions both companies to capitalize on unmet needs in a market demanding more precise and innovative treatment approaches.<\/p>\n\n\n\n<p>The ProFoundry Platform integrates multi-dimensional biological data with advanced computational tools to uncover proteins within the expanded human proteome that were previously undetectable. By enabling the identification and validation of novel protein-based drug targets, the platform offers a powerful engine for first-in-class therapeutic discovery. Within the context of the Novartis collaboration, this technology provides a differentiated approach to address <a href=\"https:\/\/www.delveinsight.com\/blog\/cardiovascular-diseases\">cardiovascular diseases<\/a> by tapping into unexplored biological space, aligning with the industry\u2019s shift toward precision-driven innovation.<\/p>\n\n\n\n<p>Under the terms of the 4-year agreement, ProFound will receive <strong>USD 25 million<\/strong> in upfront and near-term milestone payments, with the potential to earn up to <strong>USD 750 million<\/strong> in downstream milestones for each selected target, along with tiered royalties.&nbsp;<\/p>\n\n\n\n<p>This structure reflects a risk-sharing model increasingly adopted in high-stakes research and development collaborations, allowing Novartis to access novel cardiovascular targets while managing early-stage development risk. For ProFound, the deal validates its platform\u2019s commercial potential and offers a significant non-dilutive funding stream to accelerate innovation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-lilly-to-acquire-verve-therapeutics-in-deal-worth-up-to-usd-1-3-billion-to-advance-one-time-gene-editing-therapies-targeting-cardiovascular-disease\"><span class=\"ez-toc-section\" id=\"Lilly_to_Acquire_Verve_Therapeutics_in_Deal_Worth_Up_to_USD_13_billion_to_Advance_One-Time_Gene_Editing_Therapies_Targeting_Cardiovascular_Disease\"><\/span><strong>Lilly to Acquire Verve Therapeutics in Deal Worth Up to USD 1.3 billion to Advance One-Time Gene Editing Therapies Targeting Cardiovascular Disease<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In <strong>June 2025<\/strong>, <strong>Eli Lilly<\/strong> signed a definitive deal to acquire <strong>Verve Therapeutics<\/strong>, strengthening its position in gene editing for cardiovascular disease. The move gives Lilly access to Verve\u2019s <em>in vivo<\/em> CRISPR platform targeting lifelong LDL reduction, aligning with its push into one-time, curative therapies for chronic conditions.<\/p>\n\n\n\n<p>Eli Lilly\u2019s planned acquisition of Verve Therapeutics marks a bold bet on one-time gene editing for <a href=\"https:\/\/www.delveinsight.com\/report-store\/atherosclerotic-cardiovascular-disease-ascvd-market\">Atherosclerotic Cardiovascular Disease (ASCVD)<\/a>. Verve\u2019s lead asset, <strong>VERVE-102<\/strong>, is a potential first-in-class in vivo base editing therapy targeting PCSK9, designed to permanently lower LDL-C through a single IV dose using proprietary GalNAc-LNP (N-acetylgalactosamine\u2013conjugated lipid nanoparticle) delivery. Backed by the US FDA <strong>Fast Track status<\/strong> and promising <strong>Phase I<\/strong> data in <a href=\"https:\/\/www.delveinsight.com\/report-store\/heterozygous-familial-hypercholesterolemia-hefh-market\">Heterozygous Familial Hypercholesterolemia (HeFH)<\/a> and premature Coronary Artery Disease (CAD), VERVE-102 is set to enter <strong>Phase II<\/strong> in <strong>H2 2025<\/strong>.<\/p>\n\n\n\n<p><em>\u201cVERVE-102 has the potential to be the first in vivo gene editing therapy for broad patient populations and could shift the treatment paradigm for cardiovascular disease from chronic care to one-and-done treatment.\u201d&nbsp;<\/em><\/p>\n\n\n\n<p>&#8211; <em>Ruth Gimeno, Lilly group vice president, Diabetes and Metabolic Research and Development<\/em><\/p>\n\n\n\n<p>Under the agreement, Lilly will acquire Verve Therapeutics for approximately <strong>USD 1 billion<\/strong> in cash through a tender offer, with the potential total deal value rising to <strong>USD 1.3 billion<\/strong> contingent on a Contingent Value Right (CVR). The CVR is tied to a key clinical milestone\u2014dosing the first ASCVD patient in a US Phase III trial of VERVE-102 within ten years\u2014underscoring Lilly\u2019s confidence in the long-term potential of Verve\u2019s lead program. The absence of financing conditions and an expected close in Q3 2025 highlight Lilly\u2019s strategic urgency, while the CVR structure aligns value realization with pipeline progress, minimizing upfront risk.<\/p>\n\n\n\n<p>Lilly\u2019s move to acquire Verve reflects the growing industry confidence in one-time gene editing as a disruptive force in cardiology. The deal adds long-term optionality to Lilly\u2019s pipeline while signaling its intent to lead in next-generation cardiovascular care.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-novartis-completes-usd-3-1-billion-acquisition-of-anthos-therapeutics-to-advance-abelacimab-a-late-stage-factor-xi-inhibitor-targeting-stroke-and-cancer-associated-thrombosis\"><span class=\"ez-toc-section\" id=\"Novartis_Completes_USD_31_billion_Acquisition_of_Anthos_Therapeutics_to_Advance_Abelacimab_a_Late-Stage_Factor_XI_Inhibitor_Targeting_Stroke_and_Cancer-Associated_Thrombosis\"><\/span><strong>Novartis Completes USD 3.1 billion Acquisition of Anthos Therapeutics to Advance Abelacimab, a Late-Stage Factor XI Inhibitor Targeting Stroke and Cancer-Associated Thrombosis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In <strong>April 2025<\/strong>, <strong>Novartis<\/strong> acquired <strong>Anthos Therapeutics<\/strong> in a transaction worth up to <strong>USD 3.1 billion<\/strong>, regaining full ownership of <strong>abelacimab<\/strong>. Anthos was founded in <strong>2019<\/strong> by <strong>Blackstone Life Sciences<\/strong> and Novartis to advance abelacimab, a novel Factor XI inhibitor originally developed at Novartis, under an exclusive global license. The acquisition underscores Novartis\u2019s renewed focus on next-generation anticoagulants that aim to deliver effective stroke prevention with an improved bleeding risk profile.<\/p>\n\n\n\n<p>Abelacimab, a fully human monoclonal antibody targeting Factor XI, introduces a novel anticoagulation approach by mimicking the protective effects of natural Factor XI deficiency. It is currently being evaluated in three <strong>Phase III trials<\/strong>\u2014LILAC-TIMI 76 for stroke prevention in <a href=\"https:\/\/www.delveinsight.com\/report-store\/atrial-fibrillation-market\">atrial fibrillation<\/a>, and ASTER and MAGNOLIA for cancer-associated thrombosis\u2014with data expected in the <strong>second half of 2026<\/strong>. Backed by two US <strong>FDA Fast Track Designations<\/strong>, abelacimab is well-positioned as a potential first-in-class therapy that addresses a critical need for safer anticoagulation, with a regulatory filing for atrial fibrillation anticipated in <strong>2027<\/strong>.<\/p>\n\n\n\n<p><em>\u201cResearch shows that 40% of patients with atrial fibrillation are not receiving optimal treatment when it comes to anticoagulation, in large part due to a fear of bleeding. This includes people living with atrial fibrillation who have a higher risk of bleeding, such as the elderly, patients taking antiplatelet agents, and those with other co-morbidities.\u201d&nbsp;<\/em><\/p>\n\n\n\n<p>&#8211; <em>Dan Bloomfield, MD, chief medical officer of Anthos Therapeutics<\/em><\/p>\n\n\n\n<p>Under the terms of the deal, Anthos shareholders will receive up to <strong>USD 3.1 billion<\/strong> in total consideration, comprising a <strong>USD 925<\/strong> <strong>million<\/strong> upfront payment and additional milestone-based payments tied to regulatory and commercial achievements. This structure reflects Novartis\u2019s confidence in abelacimab\u2019s long-term potential while aligning payouts with key value-inflection points.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-conclusion-sealing-the-next-era-of-cardiovascular-innovation\"><span class=\"ez-toc-section\" id=\"Conclusion_Sealing_the_Next_Era_of_Cardiovascular_Innovation\"><\/span><strong>Conclusion: Sealing the Next Era of Cardiovascular Innovation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The landmark deals of 2025 mark more than a flurry of high-value transactions\u2014they signal a strategic redefinition of cardiovascular medicine. From mining the hidden layers of the proteome to rewriting the genome itself, and from safer anticoagulation to curative therapies, big pharma\u2019s bets are converging on one goal: transforming outcomes in a field long dominated by incremental gains. As Novartis, Lilly, and others stake billions on precision, durability, and first-in-class potential, the competitive edge will belong to those who can marry bold science with executional discipline. If these pipelines deliver, the next decade could see cardiovascular care shift from managing disease to decisively altering its course\u2014turning today\u2019s breakthrough deals into tomorrow\u2019s new standard of care.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/pcsk9-inhibitors-psck9i-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/05160304\/PCSK9-Inhibitors-Market-Assessment-1024x194.webp\" alt=\"PCSK9 Inhibitors Market Assessment\" class=\"wp-image-33259\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/05160304\/PCSK9-Inhibitors-Market-Assessment-1024x194.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/05160304\/PCSK9-Inhibitors-Market-Assessment-300x57.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/05160304\/PCSK9-Inhibitors-Market-Assessment-150x28.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/05160304\/PCSK9-Inhibitors-Market-Assessment-768x145.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/05160304\/PCSK9-Inhibitors-Market-Assessment-1536x291.webp 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/05160304\/PCSK9-Inhibitors-Market-Assessment.webp 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>The cardiovascular space has witnessed a surge in strategic collaborations and licensing deals as companies race to address the rising global burden of heart disease with next-generation therapies. Recent transactions reflect a sharpened focus on precision cardiology, novel protein targets, and RNA-based approaches, underscoring the industry\u2019s shift toward innovation-driven growth. These alliances not only aim [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":33260,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[21694,97,22697,143,19062,18083,19808,19809],"industry":[17225],"therapeutic_areas":[17242],"class_list":["post-33257","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-atherosclerotic-cardiovascular-disease","tag-atrial-fibrillation","tag-cardiovascular-deals","tag-cardiovascular-disease","tag-cardiovascular-disease-burden","tag-heterozygous-familial-hypercholesterolemia","tag-pcsk9-inhibitors","tag-pcsk9-inhibitors-market","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Landmark Cardiovascular Deals of 2025<\/title>\n<meta name=\"description\" content=\"Cardiovascular space has witnessed surge in strategic collaborations and licensing deals as companies race to address rising global burden.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/cardiovascular-deals-2025\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Landmark Cardiovascular Deals of 2025\" \/>\n<meta property=\"og:description\" content=\"Cardiovascular space has witnessed surge in strategic collaborations and licensing deals as companies race to address rising global burden.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/cardiovascular-deals-2025\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-05T10:36:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-05T10:36:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/05160521\/cardiovascular-deals-2025.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Landmark Cardiovascular Deals of 2025","description":"Cardiovascular space has witnessed surge in strategic collaborations and licensing deals as companies race to address rising global burden.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/cardiovascular-deals-2025","og_locale":"en_US","og_type":"article","og_title":"Landmark Cardiovascular Deals of 2025","og_description":"Cardiovascular space has witnessed surge in strategic collaborations and licensing deals as companies race to address rising global burden.","og_url":"https:\/\/www.delveinsight.com\/blog\/cardiovascular-deals-2025","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-09-05T10:36:16+00:00","article_modified_time":"2025-09-05T10:36:17+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/05160521\/cardiovascular-deals-2025.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/cardiovascular-deals-2025","url":"https:\/\/www.delveinsight.com\/blog\/cardiovascular-deals-2025","name":"Landmark Cardiovascular Deals of 2025","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/cardiovascular-deals-2025#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/cardiovascular-deals-2025#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/05160521\/cardiovascular-deals-2025.webp","datePublished":"2025-09-05T10:36:16+00:00","dateModified":"2025-09-05T10:36:17+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Cardiovascular space has witnessed surge in strategic collaborations and licensing deals as companies race to address rising global burden.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/cardiovascular-deals-2025"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/cardiovascular-deals-2025#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/05160521\/cardiovascular-deals-2025.webp","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/05160521\/cardiovascular-deals-2025.webp","width":466,"height":284,"caption":"cardiovascular-deals-2025"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/05160521\/cardiovascular-deals-2025-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Atherosclerotic Cardiovascular Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Atrial Fibrillation<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cardiovascular Deals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cardiovascular disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">cardiovascular disease burden<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Heterozygous Familial Hypercholesterolemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PCSK9 inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PCSK9 inhibitors market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Atherosclerotic Cardiovascular Disease<\/span>","<span class=\"advgb-post-tax-term\">Atrial Fibrillation<\/span>","<span class=\"advgb-post-tax-term\">Cardiovascular Deals<\/span>","<span class=\"advgb-post-tax-term\">Cardiovascular disease<\/span>","<span class=\"advgb-post-tax-term\">cardiovascular disease burden<\/span>","<span class=\"advgb-post-tax-term\">Heterozygous Familial Hypercholesterolemia<\/span>","<span class=\"advgb-post-tax-term\">PCSK9 inhibitors<\/span>","<span class=\"advgb-post-tax-term\">PCSK9 inhibitors market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 months ago","modified":"Updated 8 months ago"},"absolute_dates":{"created":"Posted on Sep 5, 2025","modified":"Updated on Sep 5, 2025"},"absolute_dates_time":{"created":"Posted on Sep 5, 2025 4:06 pm","modified":"Updated on Sep 5, 2025 4:06 pm"},"featured_img_caption":"cardiovascular-deals-2025","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33257","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=33257"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33257\/revisions"}],"predecessor-version":[{"id":33262,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33257\/revisions\/33262"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/33260"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=33257"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=33257"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=33257"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=33257"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=33257"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}